Currently, Atara Biotherapeutics Inc’s (ATRA) stock is trading at $0.57, marking a gain of 11.18% from last night’s close. At this price, the stock is -89.95% below its 52-week high of $5.64 and 185.50% above its 52-week low of $0.20. Based on the past 30-day period, the stock price is -61.07% below the high and +184.24% above the low.

The 200-day Simple moving average is often placed more emphasis on by traders because of daily price changes. Investors will use the SMA-200 in different situations in trading activity as a key indicator to determine their support and resistance levels, and at the moment, ATRA’s SMA-200 is $2.1925.

As well, it is important to consider ATRA stock ratios such as price-to-sales, which is currently 12.73.

How does Atara Biotherapeutics Inc (ATRA) stock rate among analysts? Buy, sell, or hold?

The key to trading is to concentrate on the future rather than on the past. During uncertain times, it can be hard to make decisions. The analysts who understand how a market works are usually the most accurate at forecasting its future. Currently, there are 9 brokerage firms that recommend the stock as a Moderate Buy. The ratings are commonly aggregated into a single number between 1 and 5. Buy or strong buy is scored 5, outperform is scored 4, hold is scored 3, underperform is scored 2 and strong sell is 1. Using a scale of 1-5, the current average recommendation is 3.22 in simple terms.

Atara Biotherapeutics Inc (ATRA): Earnings History

If we examine Atara Biotherapeutics Inc’s recent earnings history, in the last quarter ended on 9/29/2023, it posted adjusted earnings per share of -$0.66, slashing the consensus of -$0.66. In other words, it beat the consensus by $0, resulting in a 0.00% surprise. In the 3 months period before the previous quarter which was closed on 9/29/2023, the stock recorded adjusted earnings per share of -$0.66 in contrast with the Outlook of -$0.66. That was a difference of $0 and a surprise of 0.00%.

Atara Biotherapeutics Inc (ATRA): Earnings History

Most analysts expect public companies to report earnings and revenue in line with their projections, but sometimes these figures vary from what they actually expected. In the current quarter, the company had earnings predictions made by 3 different analysts, who are expecting earnings to fall in between the range of -0.50 and -0.62 with an average Earnings Estimate of -0.57 which is in contrast with the last year earnings estimate of -0.72 and also replicates 20.83% growth rate year over year.

Atara Biotherapeutics Inc (NASDAQ: ATRA) Ownership Details

I will give a breakdown of the key shareholders in Atara Biotherapeutics Inc (ATRA). Recent figures show that the company’s insiders hold 2.58% of shares. A total of 194 institutional investors hold shares in the company, making 107.64% of its stock and 110.50% of its float.

Sep 29, 2023, it was reported that the Company‚Äôs largest institutional holder is Baupost Group, Inc,.(The) LLC holding total of 9.77 million shares that make 9.59% of the company’s total number of shares and are currently priced at 5.49 million.

The securities firm JP Morgan Chase & Company holds 8.67 million shares of ATRA, making it the second largest institutional shareholder. Taking this into account, the holding percentage comes to 8.50%, and the holding percentage of shares is valued at 4.87 million.

An overview of Atara Biotherapeutics Inc’s technicals

In order to learn about trade movements and investor behavior, it is best to analyze the short, medium, and long term technical indicators along with the average volume of a stock. A 20-day average of the stock’s daily volume suggests Atara Biotherapeutics Inc (ATRA) traded 8,677,098 shares per day, with a moving average of $0.9215 and price change of -0.7655. With the moving average of $1.2922 and a price change of -1.1155, about 4,196,343 shares changed hands on average over the past 50 days. Finally, ATRA’s 100-day average volume is 2,681,490 shares, alongside a moving average of $1.5608 and a price change of -1.0655.

Leave a Reply

Your email address will not be published. Required fields are marked *